… design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR‐HF) study: a randomized, placebo‐controlled study of intravenous …

SD Anker, JC Colet, G Filippatos… - European journal of …, 2009 - Wiley Online Library
… Another study by Okonko et al.33 confirmed benefits of iv iron loading with iron sucrose in …
and abnormal iron metabolism to 16 weeks of iv iron sucrose or no treatment. Iron therapy was …

Rationale and design of a randomised trial of intravenous iron in patients with heart failure

PR Kalra, JGF Cleland, MC Petrie, FZ Ahmed… - Heart, 2022 - heart.bmj.com
… The Effectiveness of Intravenous iron treatment versus standard care in patients with heart
failure and iron deficiency (IRONMAN) trial evaluated whether the benefits of intravenous iron

Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial

PS Myles, T Richards, A Klein, J Smith, EM Wood… - American Heart …, 2021 - Elsevier
intravenous (IV) iron therapy thus may improve anemia and therefore patient outcome
following cardiac surgery. We have initiated the intravenous iron for … surgery, IV iron will reduce …

… of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design

LA Szczech, DB Bregman, RA Harrington… - Nephrology Dialysis …, 2010 - academic.oup.com
… Ferric carboxymaltose (FCM) is a novel IV iron formulation designed to permit larger
infusions compared to currently available IV standards such as Venofer® (iron sucrose). …

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized …

NF Adkinson, WE Strauss, K Bernard… - Journal of Blood …, 2017 - Taylor & Francis
… However, IV iron treatment has been associated with acute hypersensitivity reactions. The
comparative risk of adverse events (AEs) with IV iron preparations has been assessed by a …

Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients …

SJ Tu, AD Elliott, N Hanna-Rivero, C Gallagher… - BMJ open, 2021 - bmjopen.bmj.com
Iron deficiency (ID) is prevalent in patients with AF. Correction of ID in other patient
populations with intravenous iron supplementation has been shown to be a safe, convenient and …

Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy

P Martens, M Dupont, J Dauw, F Somers… - ESC Heart …, 2019 - Wiley Online Library
intravenous iron on reverse remodelling in HFrEF are scarce. Toblli et al. demonstrated that
repeated treatment with iron … was small, used an intravenous iron formulation that is currently …

Supplementation of iron in pulmonary hypertension: rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension

LSGE Howard, GMJ Watson, J Wharton… - Pulmonary …, 2013 - journals.sagepub.com
… We propose that intravenous iron replacement will improve hemodynamics and clinical
outcomes in IPAH. If the data supports a potentially useful therapeutic effect and suggest this …

Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia

L Beck-da-Silva, LE Rohde, AC Pereira-Barretto… - Journal of cardiac …, 2007 - Elsevier
… alone or combination of erythropoietin and intravenous iron. However, the effect of iron
supplementation alone in HF patients with ACD, ferropenic anemia, or both is unknown. …

[HTML][HTML] Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in …

KA Barraclough, E Noble, D Leary, F Brown… - BMC nephrology, 2009 - Springer
… patients), in whom repeated intravenous cannulation is logistically more difficult. Our … iron
versus 2-monthly intravenous iron infusions in 28 PD patients and demonstrated that IV iron